Alkem Labs reported Q1 FY27 revenue of INR 3,740 Cr (+11% YoY), with India sales up 10.3% and International up 16%. EBITDA margin was 20.5%, while net profit degrew 21.7% due to taxation.

The company outperformed the Indian pharma market by 100 bps.

Management expects ~12% India growth for FY27, despite Trade Generics drag.

U.S. growth is projected mid-to-high single-digit.

The Daman facility received OAI status, but supplies continue without interruption; resolution is expected in 6-12 months.

U.S.

CDMO business had INR 60 Cr quarterly operational expense, targeting breakeven at USD 25-30 million annual revenue by FY28. Occlutech acquisition targets INR 400 Cr sales with breakeven EBITDA this year.

The company focuses on strategic execution and operational efficiency.